MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurjpc/zwac172

Медицинская библиотека · European journal of preventive cardiology · 2022

Uptake of prescription smoking cessation pharmacotherapies after hospitalization for major cardiovascular disease.

Robijn Annelies L, Woodward Mark, Pearson Sallie-Anne, Hsu Benjumin, Chow Clara K, Filion Kristian B, Jorm Louisa, Havard Alys

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: We determined the prevalence of prescription smoking cessation pharmacotherapy (SCP) use after hospitalization for major cardiovascular disease (MCD) among people who smoke and whether this varies by sex.

METHODS AND

RESULTS

We conducted a population-based cohort study including all people hospitalized in New South Wales, Australia, between July 2013 and December 2018 (2017 for private hospitals) with an MCD diagnosis. For patients who also had a diagnosis of current tobacco use, we used linked pharmaceutical dispensing records to identify prescription SCP dispensings within 90 days post-discharge. We determined the proportion who were dispensed an SCP within 90 days, overall and by type of SCP. We used logistic regression to estimate the odds of females being dispensed an SCP relative to males. Of the 150 758 patients hospitalized for an MCD, 20 162 (13.4%) had a current tobacco use diagnosis, 31% of whom were female. Of these, 11.3% (12.4% of females, 10.9% of males) received prescription SCP within 90 days post-discharge; 3.0% were dispensed varenicline, and 8.3% were dispensed nicotine replacement therapy patches. Females were more likely than males to be dispensed a prescription SCP [odds ratio (OR) 1.16, 95% confidence interval (CI) 1.06-1.27)]; however, this was not maintained after adjusting for potential confounders (adjusted OR 1.04, 95% CI 0.94-1.15).

CONCLUSION

Very few females and males who smoke use prescription SCPs after hospitalization for an MCD. The use of varenicline, the SCP with the highest efficacy, was particularly low. This represents a missed opportunity to increase smoking cessation in this high-risk population, thereby reducing their risk of recurrent cardiovascular events.

Для цитирования: Robijn Annelies L, Woodward Mark, Pearson Sallie-Anne, Hsu Benjumin, Chow Clara K, Filion Kristian B, Jorm Louisa, Havard Alys. Uptake of prescription smoking cessation pharmacotherapies after hospitalization for major cardiovascular disease.. European journal of preventive cardiology. 2022. DOI: 10.1093/eurjpc/zwac172.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.